Appleby Bermuda advised Sumitomo Dainippon Pharma Co., Ltd., a leading TSE listed (TYO:4506) Japanese pharmaceutical company in respect of its estimated  USD 3 billion acquisition of 5 biopharma companies via the transfer by Roivant Sciences Ltd. of its ownership interests in Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd., and Spirovant Sciences Ltd to Sumitovant Biopharma Ltd., a wholly owned subsidiary of Sumitomo.

Partner Brad Adderley led the deal with assistance from Partner Gary Harris and Associate Jamie Rego. Brad said, “We are pleased to have acted as Bermuda counsel to Sumitomo Dainippon Pharma on this significant acquisition and wish them continued success.”

Twitter LinkedIn Email Save as PDF
More Deals